BIIBBiogen Inc.
AI adoption · Q1 2026 earnings call
Health CareExploring
1
extracted from this call
2 / 5
directional only
Not disclosed
no breakout in this call
AI was not meaningfully discussed on this call. The only relevant data-driven technology reference was to a 'next best action' field tool for SKYCLARYS patient finding, which Alicia Alaimo described as informing rep targeting, but this was not explicitly labeled as AI or machine learning. No AI products, AI partnerships, AI infrastructure investments, or AI strategy were discussed.
Adopter
See full leaderboard →17/ 100
24
stage: exploring · max spec: 2
0
no quantified disclosure
35
1 scope
internal_use
1 AI mention from this call.
Extracted verbatim from the BIIB Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T2Q&A· President· Internal useI'd love to drill down a little more on the strength we saw with SKYCLARYS. Can you walk me through some of the drivers of this?
“we are now at the launch phase where we are going out, we are using our patient finding our next best action in the field where our reps every week receive a list of all the different offices they can go visit because we believe the patient is there, and then they go on the hunt.”
— Alisha Alaimo, BIIB earnings callSKYCLARYS
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No AI or machine learning commentary was offered in prepared remarks.
- The 'next best action' field tool mentioned for SKYCLARYS patient identification was not explicitly attributed to AI/ML by management; it may involve algorithmic targeting but was not labeled as such.
- No analyst asked about AI strategy, AI-driven drug discovery, or AI in operations.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.